# Advances in the study of gut microecology and mechanisms of hyperuricemia and gouty arthritis

**Authors:** Youliang Zhang, Hengyu Zhang, Tianwen Miao, Xuetao Wang, Yanan Zuo, Renwei Zhang, Liangtong Zhang, Yuan Cheng, Dong Liu, Xin Chen, Longcan Li, Xingwen Xie, Ning Li

PMC · DOI: 10.3389/fimmu.2025.1738716 · 2026-01-08

## TL;DR

This paper reviews how gut microbes influence gout and high uric acid, and explores new treatments like probiotics.

## Contribution

The paper synthesizes recent findings on gut microbiota's role in gout and hyperuricemia, highlighting novel therapeutic strategies.

## Key findings

- Gut microbiota modulates purine metabolism and uric acid levels, impacting gout development.
- Dysbiosis in the gut can trigger immune responses and inflammation linked to gouty arthritis.
- Probiotics and fecal microbiota transplantation show promise as therapeutic interventions.

## Abstract

Gouty arthritis is a metabolic disorder caused by purine metabolism dysregulation, characterized by monosodium urate crystal deposition in and around joints, triggering acute articular inflammation via NLRP3 inflammasome activation and IL-1β-mediated inflammatory cascades. While hyperuricemia represents a critical biochemical prerequisite for gouty arthritis development, elevated serum urate levels do not invariably lead to the disease. Mounting evidence suggests a significant relationship between gut microbiota and the pathogenesis of both gouty arthritis and hyperuricemia. The gut microbial ecosystem influences host health through metabolic and immune function modulation, performing essential roles in digestion, energy harvesting, and short-chain fatty acid production. Intestinal dysbiosis can damage epithelial integrity, compromise immune tolerance, and activate immune cells, thus contributing to disease onset and progression. Elucidating the complex interactions between gut microbiota and the mechanisms underlying gouty arthritis and hyperuricemia presents promising opportunities for developing novel preventative and therapeutic interventions. This review synthesizes recent advances in understanding the gut-joint axis and evaluates emerging therapeutic strategies including probiotics, dietary interventions, and fecal microbiota transplantation.

## Linked entities

- **Proteins:** NLRP3 (NLR family pyrin domain containing 3), IL1B (interleukin 1 beta)
- **Diseases:** hyperuricemia (MONDO:0002144)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}
- **Diseases:** hyperuricemia (MESH:D033461), Intestinal dysbiosis (MESH:D064806), Gouty arthritis (MESH:D015210), metabolic disorder (MESH:D008659), articular inflammation (MESH:D007249)
- **Chemicals:** monosodium urate (MESH:D014527), short-chain fatty acid (MESH:D005232)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12823916/full.md

---
Source: https://tomesphere.com/paper/PMC12823916